Current management of pediatric dilated cardiomyopathy

Current Opinion in Cardiology

Volumn 25, Issue 2, 2010, Pages 80-87

  Silva, Jennifer N A ^a   Canter, Charles E ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Dilated cardiomyopathy; Pediatrics; Treatment

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; INOTROPIC AGENT; NESIRITIDE; VASODILATOR AGENT;

ARTIFICIAL VENTILATION; CARDIAC RESYNCHRONIZATION THERAPY; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MITRAL ANNULOPLASTY; MUSCULAR DYSTROPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS; REVIEW; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY, DILATED; CHILD; CHILD WELFARE; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 76749099296     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328335b220     Document Type: Review

References (98)

1. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296:1867-1876.
2. Daubeney PEF, Nugent AW, Chondros P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population study. Circulation 2006; 114:2671-2678.
3. Andrews RE, Fenton MJ, Ridout DA, et al. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation 2008; 117:79-84.
4. Arola A, Tuominen J, Ruuskanen O, et al. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 1998; 101:369-376. (Pubitemid 28136408)
5. O'Sullivan JJ, Roche SL, Crossland DS, et al. Recovery of heart function in children with acute severe heart failure. Transplantation 2008; 85:975-979.
6. Tsirka AE, Trinkaus K, Chen S-C, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 2004; 44:391-397.
7. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults - a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines - developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:177-2016.
8. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Failure 2008; 8:933-989.
9. Harmon WG, Sleeper LA, Cuniberti L, et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol 2009; 104:281-286.
10. Grenier MA, Osganian SK, Cox GF, et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J 2000; 139:S86-95.
11. Cochrane AD, Coleman DM, Davis AM, et al. Excellent long-term functional outcome after an operation for anomalous left coronary artery from the pulmonary artery. J Thorac Cardiovasc Surg 1999; 117:332-342.
12. Medi C, Kalman J, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia. J Am Coll Cardiol 2009; 53:1791-1797.
13. Sullivan MS, Allgrove J, Yates R, et al. Hypocalcemia and vitamin D deficiency: an important, but preventable cause of life-threatening infant heart failure. Heart 2008; 94:581-584.
14. Schwartz ML, Cox GF, Lin AE, et al. Clinical approach to genetic cardiomyopathy in children. Circulation 1996; 94:2021-2038.
15. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 2007; 24:15-25.
16. Chen L-R, Chen C-A, Chiu S-N, et al. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe Disease. J Pediatr 2009; 155:271-275.
17. Helton E, Darragh R, Francis P, et al. Metabolic aspects of myocardial disease and a role of L-carnitine in the treatment of childhood cardiomyopathy. Pediatrics 2000; 105:1260-1270.
18. Gagliardi MG, Bevilacqua M, Bassano C, et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004; 90:1167-1171.
19. Drucker NA, Colan SD, Lewis AB, et al. g-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89:252-257.
20. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333:269-275.
21. McNamara Dm, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254-2259.
22. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis. Virological and immunological profile of responders versus nonresponders. Circulation 2003; 107:857-863.
23. Cooper LT. Myocarditis. N Engl J Med 2009; 360:1526-1538.
24. Foerster S, Canter C, Carey A, et al. A comparative analysis of outcome for pediatric patients with biopsy-proven myocarditis, clinical-diagnosed myocarditis, and idiopathic dilated cardiomyopathy (abstract). Circulation 2007; 107 (Suppl II):II-565.
25. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429-1435.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
27. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, losinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2313-2318.
28. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450-1456.
29. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
30. Packer M, Bristor MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355. (Pubitemid 26152713)
31. Packer M, Fowler MB, Roecker EB, et al. Effects of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194-2199.
32. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinic outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003; 362:7-13.
33. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362:767-771. (Pubitemid 37093916)
34. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776. (Pubitemid 37093917)
35. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
36. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
37. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
38. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525-533.
39. Ross RD. Medical management of chronic heart failure in children. Am J Cardiovasc Drugs 2001; 1:37-44.
40. Leitch CA. Growth, nutrition and energy expenditure in pediatric heart failure. Prog Pediatr Cardiol 2000; 11:195-202.
41. Lipshultz SE, Alvarez JA, Sully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94:525-533.
42. Carver JR, Shapiro CL, Ng A, et al., ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991-4008.
43. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
44. Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45:855-857.
45. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517-4522.
46. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991; 83:523-527.
47. Leversha AM, Wilson NJ, Clarkson PM, et al. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child 1994; 70:35-39.
48. Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young 1992; 2:14-19.
49. Stern H, Weil J, Genz T, et al. Captopril in children with dilated cardiomyopathy: acute and long-termeffects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol 1990; 11:22-28.
50. Schiffman H, Gawlik L, Wessel A. Treatment effects of captopril in neonates, infants and young children with congestive heart failure. Z Kardiol 1996; 85:709.
51. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14:9-12.
52. Flynn JT, Meyers KC, Pacheo Neto J, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 15 years. Hypertension 2008; 52:222-228.
53. Margossian R. Contemporary management of pediatric heart failure. Expert Rev Cardiovasc Ther 2008; 6:187-197.
54. Rosenthal D, Chrisant MRK, Edens E, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23:1313-1333.
55. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138:505-511.
56. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 2002; 21:906-909.
57. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multiinstitutional experience. J Heart Lung Transplant 1999; 18:269-274.
58. Läer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143:916-922.
59. Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27:336-342.
60. Rusconi P, Gómex-MaŕnO, Rossique-González M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004; 23:832-838.
61. Azeka E, Franchini Ramieres JA, Valler C, et al. Delisting of infants and children from the heart transplantation waiting list after carvedilol therapy. J Am Coll Cardiol 2002; 40:2034-2038.
62. Shaddy RE, Boucke MM, Hsu DT, et al., Pediatric Carvedilol Study Group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:1171-1179.
63. Foerster S, Canter CE. Pediatric heart failure therapy with b-adrenoceptor antagonists. Pediatr Drugs 2008; 10:125-134.
64. McAlister FA, Stewart S, Ferrua J, McMurray JJV. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44:810-819.
65. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329-1338.
66. Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients. An international multicenter study. J Am Coll Cardiol 2005; 46:2277-2283.
67. Cecchin F, Frangini PA, Brown DW, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease. J Cardiovasc Electrophysiol 2009; 20:58-65.
68. Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchronization therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009; 95:1165-1171.
69. Berul C. Pacing treatment for dilated cardiomyopathy: optimization of resynchronization pacing in pediatrics. Curr Opin Cardiol (in press).
70. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003; 91:538-543.
71. Badhwar V, Bolling SF. Mitral valve surgery in the patient with left ventricular dysfunction. Semin Thorac Cardiovasc Surg 2002; 14:133-136.
72. Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARRILLON mitral annuloplasty device European Union study. Circulation 2009; 120:326-333.
73. Breinholt JP, Fraser CD, Dreyer WJ, et al. The efficacy of mitral valve surgery in children with dilated cardiomyopathy and severe mitral regurgitation. Pediatr Cardiol 2008; 29:13-18.
74. Walsh MA, Benson LN, Dipchand AI, et al. Surgical repair of the mitral valve in children with dilated cardiomyopathy and mitral regurgitation. Ann Thorac Surg 2008; 85:1085-1088.
75. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114: 135-142.
76. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
77. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151-2158.
78. Rhee EK, Canter CE, Basile S, et al. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant 2007; 26:447-452.
79. Pahl E, Canter CE, Colan SD, et al. Sudden death in 1803 children with dilated cardiomyopathy: rates and risk factors [abstract]. Circulation (in press).
80. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circulation 2009; 119:1616-1624.
81. John JB, Cron SG, Kung GC, et al. Intracardiac thrombi in pediatric patients: presentation profiles and clinical outcomes. Pediatr Cardiol 2007; 28:213-220.
82. McCrindle BW, Karamlou T, Wong H, et al. Presentation, management, and outcomes of thrombosis for children with cardiomyopathy. Can J Cardiol 2006; 22:685-690.
83. Behera SK, Zuccaro JC, Wetzel GT, et al. Nesiritide improves hemodynamics in children with dilated cardiomyopathy: a pilot study. Pediatr Cardiol 2009; 30:26-34.
84. Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric and congenital heart disease. An American Heart Association Scientific Statement. Circulation 2007; 115:658-676.
85. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric heart transplantation report: 2008. J Heart Lung Transplant 2008; 27:970-977.
86. Kirk R, Naftel D, Hoffman TM, et al. Outcome of pediatric patients with dilated cardiomyopathy listed for transplant: a multiinstitutional study. J Heart Lung Transplant 2009. [Epub ahead of print]
87. Almond CSD, Thiagarajan RR, Piercy GE, et al. Waiting list mortality among children for heart transplantation in the United States. Circulation 2009; 119:717-727.
88. Blume ED, Naftel DC, Bastardi HJ, et al. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multiinstitutional study. Circulation 2006; 113:2313-2319.
89. Paulks LB,Ündar A. New devices for pediatric mechanical circulatory support. Curr Opin Cardiol 2008; 23:91-96.
90. Gandhi SK, Huddleston CB, Balzer DT, et al. Biventricular assist devices as a bridge to heart transplantation in small children. Circulation 2008; 118 (Suppl 1):S89-S93.
91. Imamura M, Dossey AM, Prodham P, et al. Bridge to cardiac transplant in children: Berlin Heart versus extracorporealmembrane oxygenation.AnnThorac Surg 2009; 87:1894-1901.
92. Davies RR, Russo MJ, Hong KN, et al. The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2008; 135:421-427.
93. Berlin Heart EXCOR Pediatric Update; September 2009.
94. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355:1873-1884.
95. Shaddy RE. Drug trials in pediatric heart failure: hype or improved clinical science? Future Cardiol 2006; 2:281-286.
96. Baldwin JT, Borovetz HS, Duncan BW, et al. The National Heart, Lung, and Blood Institute Pediatric Circulatory Support Program. Circulation 2006; 1113:147-155.
97. Auerbach SR, Manlhiot C, Reddy S, et al. Recipient genotype is a predictor of allograft cytokine expression and outcomes after pediatric cardiac transplantation. J Am Coll Cardiol 2009; 53:1909-1917.
98. Yamada S, Nelson TJ, Crespo-Diaz RJ, et al. Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells 2008; 26:2644-2653.